Category: 234108-58-8

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.234108-58-8,tert-Butyl 4-(2-aminoethyl)-3-oxopiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

B. 4-(tert-Butyloxycarbonyl)-1-[2-(2,3 5,6-tetrachloropyridin-4-ylamino)-ethyl]-piperazin-2-one. 4-(tert-Butyloxycarbonyl)-1-(2-aminoethyl)-piperazin-2-one (4.0 g, 16 mmol) is dissolved in methylene chloride (150 ML) and treated with 4-nitro-2,3,5,6-tetrachloro-pyridine (4.8 g, 18 mmol) and N-methylmorpholine (4.0 ML, 36 mmol).The reaction mixture is stirred for 5 h, concentrated and the residue is purified by chromatography (50% ethyl acetate/hexane) to give the title compound (4.8 g, 10.5 mmol).Fab MS m/z: 457, 469, 461, [M+1]+; 1H NMR (CDCl3, 300 MHz) delta6.00 (t, 1H), 4.10 (s, 2H), 3.97 (m, 2H), 3.66 (m, 2H), 3.38 (m, 2H)., 234108-58-8

The synthetic route of 234108-58-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; AVENTIS PHARMACEUTICALS INC.; US2004/102450; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

234108-58-8, tert-Butyl 4-(2-aminoethyl)-3-oxopiperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EXAMPLE 95 1-[2-(Pyridazin-4-ylamino)-ethyl]-piperazin-2-one. 1-(2-Aminoethyl)-4-(tert-butyloxycarbonyl)-piperazin-2-one from EXAMPLE 92, Part A (1.0 g, 4.1 mmol) is treated with 3,4,5-trichloropyridazine (0.81 g, 4.1 mmol), triethylamine (0.57 ML, 4.1 mmol), THF (25 ML) and heated to 120 C. in a sealed tube for 3 hours.Upon cooling, the solution is diluted with ethyl acetate and washed with aqueous sodium bicarbonate (25 ML), water and dried over sodium sulfate.The organic layer is concentrated and chromatographed (5% methanol/methylene chloride) to give a mixture of isomers (0.8 g, 20 mmol).The mixture is dissolved in 0.5 M sodium methoxide in methanol (200 ML), treated with 10% Pd/C (0.5 g) and agitated under 50 PSI of hydrogen for 20 hours.The reaction mixture is filtered; the filtrate is concentrated to a residue which is chromatographed (NH4OH/H2O/MeOH/EtOAc, 1:1:2:90) to give crude 4-(tert-butyloxycarbonyl)-1-[2-(pyridazin-4-ylamino)-ethyl]-piperazin-2-one.This material is dissolved in a minimal amount of THF and treated with a saturated solution of HCl in ethyl acetate (50 ML).The solution is stirred at ambient temperature for 2 h and diluted with diethyl ether (50 ML).The precipitated title compoundcompound is collected and air dried (0.5 g, 1.7 mmol). MS m/z: 367, [M+1]+; 1H NMR (CD3OD, 300 MHz) delta8.8 (d, 1H), 8.5 (s, 1H), 7.4 (d, 1H), 4.1 (s, 2H), 3.5-3.8 (m, 8H).

234108-58-8, As the paragraph descriping shows that 234108-58-8 is playing an increasingly important role.

Reference£º
Patent; AVENTIS PHARMACEUTICALS INC.; US2004/102450; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics